NCT01729806View on ClinicalTrials.gov

Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 19, 2012

Primary Completion Date

March 30, 2018

Study Completion Date

March 30, 2018

Conditions
CD20 PositiveRecurrent B-Cell Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin Lymphoma
Interventions
BIOLOGICAL

Ipilimumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Rituximab

Given IV

Trial Locations (7)

27710

Duke University Medical Center, Durham

63110

Washington University School of Medicine, St Louis

90033

USC / Norris Comprehensive Cancer Center, Los Angeles

91010

City of Hope Comprehensive Cancer Center, Duarte

91030

City of Hope South Pasadena, South Pasadena

95817

University of California Davis Comprehensive Cancer Center, Sacramento

17033-0850

Penn State Milton S Hershey Medical Center, Hershey

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01729806 - Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma | Biotech Hunter | Biotech Hunter